"Leiomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
| Descriptor ID |
D007890
|
| MeSH Number(s) |
C04.557.450.590.455 C04.557.450.795.455
|
| Concept/Terms |
Leiomyosarcoma, Epithelioid- Leiomyosarcoma, Epithelioid
- Epithelioid Leiomyosarcoma
- Epithelioid Leiomyosarcomas
- Leiomyosarcomas, Epithelioid
Leiomyosarcoma, Myxoid- Leiomyosarcoma, Myxoid
- Leiomyosarcomas, Myxoid
- Myxoid Leiomyosarcoma
- Myxoid Leiomyosarcomas
|
Below are MeSH descriptors whose meaning is more general than "Leiomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Leiomyosarcoma".
This graph shows the total number of publications written about "Leiomyosarcoma" by people in this website by year, and whether "Leiomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leiomyosarcoma" by people in Profiles.
-
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 06 01; 28(11):2306-2312.
-
Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
-
Comparison of clinicopathological features and outcomes in patients with primary leiomyosarcoma of bone and soft tissue. J Surg Oncol. 2021 Apr; 123(5):1274-1283.
-
Primary iliocaval leiomyosarcomas: The path beyond surgery. Eur J Surg Oncol. 2020 05; 46(5):893-897.
-
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
-
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
-
Endometrial Stromal Sarcoma With Hyalinizing Giant Rosettes, Mimicking Low-Grade Fibromyxoid Sarcoma. Int J Surg Pathol. 2018 Sep; 26(6):525-527.
-
The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. Am J Surg Pathol. 2017 Jul; 41(7):923-931.
-
Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther. 2017 08; 17(8):717-723.
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.